TY - ADVS TI - Alemtuzumab (Campath-1H) in therapy of CLL AU - Rai, Kanti A2 - Waldmann, Herman PY - 2007 DA - 2007/10/01 N1 - Archived at 2016/06/22 UR - https://hstalks.com/bs/584/ AB - Development of Campath-1H, Burroughs-Wellcome Era (BW), Millenium (LeukosSite)-Ilex Era (MI), Differences between BW era and MI era, The two main trials in the BW era: study 005 in European countries and study 009 in the USA, Responses to these trials, Complications of these trials: opportunistic infection, MI era results from 1998 and study 211 (which incorporated prophylaxis against opportunistic infections), Efficacy of Campath-1H, Examination of bone marrow biopsy specimens, Survival times, Infectious complications after first-line therapy with Campath-1H, CMV guidelines, CALGB trial DB - The Biomedical & Life Sciences Collection SN - 2056-452X ID - 1244 PB - Henry Stewart Talks ER -